Fund moves
116 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 10, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 11, 2026 · Filed Jun 12, 2026
Johnson & Johnson's Chief TO and Risk Officer sold $2.41M of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$2,411,500
Shares × reported transaction price
58 days after results of Apr 14, 2026, 34 days before results of Jul 15, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $238.33 on Jun 11, 2026, within 5% of its 52-week high, after a 5% rise over the previous 30 trading days
52-week range $149.79 (Jun 20, 2025) to $248.56 (Mar 2, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $227.35 on Apr 29, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Kathryn E Wengel's first sale of JNJ since Jun 2023
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
FDA approved Tremfya on May 28, 2026, 14 days before this trade.
New use approved (efficacy supplement). Active ingredient: Guselkumab. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.9% | −1.4% | −0.5% |
| 30 days | +4.8% | 0.0% | +4.8% |
| 90 days | +13.0% | +0.8% | +12.2% |
Past results only. Not a forecast.
Fund moves
116 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 10, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
113 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 8, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
113 tracked managers disclosed the same change for Q2 2026. From a 13F filed Jul 8, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.